Introduction 1
Duchenne Muscular Dystrophy (DMD) is an X-linked recessive disease characterized 2 by progressive muscle degeneration and weakness 1 , which usually occurs in early 3 childhood, affecting approximately 1 in 3500 male births worldwide 2 . It is reported 4 that DMD is caused by the mutations of the DMD gene on the X chromosome 3 . 5 Current gold standards for prenatal diagnostic testing include amniocentesis or 6 chorionic villus sampling (CVS) 4 . With the discovery of cell-free fetal DNA in 7 maternal plasma 5 and the development of genetic testing methods, noninvasive 8 prenatal diagnosis (NIPD) is increasingly used in clinical practice. The feasibility and 9 accuracy of detecting fetal DNA using maternal plasma DNA have been confirmed by 1 0 a large number of studies. NIPD was initially used to detect fetal aneuploidy, but it's 1 1 application in single gene disorders has also been explored 6 . 1 2
The detection of DMD by NIPD has been researched previously, but most studies are 1 3 based on trios' strategy with a proband 7,8 . This approach can address some of the 1 4 needs of prenatal diagnosis, but for female carriers, it is unable to detect the 1 5 genotypes of their first child because there is no proband could provide assistance for 1 6 resolving haplotypes. Many efforts have been made to overcome this problem, with 1 7 microfluidics-based linked-read sequencing technology being used prominently 9 . This 1 8 is a direct haplotyping phasing approach and has been reported to predict fetal 1 9 genotypes without a proband in a family accurately. In the study published by Hui et 2 0 al. 10 , the mutation inheritance status of the fetus was successfully deduced by 2 1 integrating the linked-read sequencing technology of 10X Genomics, next-generation 2 2 targeted sequencing and relative haplotype dosage (RHDO) analysis 11 . To confirm the 2 3 accuracy of the direct haplotype-based NIPD and its feasibility for clinical application 2 4 in the case of DMD, we recruited 13 families affected by DMD for research. 
Sample collection 2
We recruited 13 high-risk families without a proband at the Third Affiliated Hospital 3 of Guangzhou Medical University and obtained informed consent. All procedures 4 were performed following the tenets of the Declaration of Helsinki and were 5 approved by the Ethics Committee of the hospital. For each family, we collected 10ml 6 maternal blood samples and 5mg CV between 11-25 weeks. 7
Maternal DNA linked-read sequencing 8
In this study, we designed a 657.29Kb SeqCap kit (Roche, Basel, Switzerland) for the 9 DMD gene detection, which contains the coding region (13.91Kb) and the flanking 1 0 region (1M) of the DMD gene, and the gender determination locus on the Y 1 1 chromosome. The peripheral blood samples of the 13 carrier mothers were collected 1 2 to obtain the genomic DNA (gDNA). Then, we isolated maternal high-molecular 1 3 weight gDNA (> 40kb) to get barcoded DNA fragments by processing with 10X 1 4
Genomics ChromiumTM library (Pleasanton, CA) protocol. Finally, we performed 1 5 targeted linked-read sequencing by using PE101 bp on Illumina Hiseq2500 1 6 sequencing system (San Diego, CA). 1 7
Plasma DNA sequencing library preparation 1 8
We used the QIAamp Circulating Nucleic Acid kit to extract cell-free DNA from 1 9 maternal plasma. Then, we prepared the library according to the protocol and 2 0 performed sequencing on the Illumina platform (Hiseq 2500). 2 1
Sequence alignment and SNP calling 2 2
We aligned the barcoded reads of maternal to the reference genome (GRCh37/hg19) 2 3 by performing 10X Lariat TM and called variants by using the GATK method in Long 2 4
Ranger. The paired-end sequencing reads of maternal plasma DNA were mapped to 2 5 the reference genome (GRCh37/hg19) using SOAP2 and the variants were 2 6 determined using GATK software. 2 7
Haplotype phasing 1
We resolved the maternal haplotypes from linked-read sequencing data of gDNA. 2 Sequenced reads that shared the same barcode with the one carrying mutant allele 3 were linked (mutant-linked barcode reads) and phased to the same haplotype. 4
Wild-type linked barcode reads were phased to the opposite haplotype. Heterozygous 5 SNPs associated with same haplotypes were used for subsequent fetal genotypic 6 prediction and recombinant detection. 7
Direct haplotype-based NIPD of the fetus 8
Because DMD is X chromosome inheritance, we focused on the SNPs of the X 9 chromosome in the following analysis process. We constructed the Hidden Markov 1 0 Model (HMM) by using maternal heterozygous SNPs on chromosome X and maternal 1 1 plasma sequencing data to infer fetal haplotype. For each site, the HMM emission 1 2 probabilities were the probabilities of genetically pathogenic and non-pathogenic 1 3 alleles in the fetus, which were calculated by analyzing the number of reads in 1 4 maternal plasma. The HMM transition probabilities were the recombination rates 1 5
between SNPs, which were obtained from the SNPs genetic map (from NCBI). When 1 6 analyzing the HMM model, we used the Viterbi algorithm to deduce the inherited 1 7 haplotype and recombination breakpoints in the fetus. 1 8
Validation of NIPD for DMD 1 9
To further verify the accuracy of NIPD, we obtained the fetal DNA by chorionic villus 2 0 sampling and performed targeted sequencing using the same probe. Thirteen families at risk for a fetus with DMD were recruited. The clinical 2 information and the mutational status of the studied cases are listed in Table 1 . 3
The results of the targeted linked-read sequencing of all the samples were listed in 4 Table 2 . The mean depth of 13 maternal gDNA samples is 561X (rang: 329X-697X) 5 and the average length of N50 phase-block is 741.61kb (range from 341.37kb to 6 963.80kb). Through the bioinformatics analysis, there were more than 98% reads 7 would map to the reference genome (GRCH37/hg19). 8
Reads that shared the same barcode and had the mutant allele at heterozygous SNP 9 positions were considered to be the mutant-linked reads, designated as Hap0, while 1 0 reads with the wild-type allele at same SNP positions were termed as Hap1. We 1 1 directly resolved the 2 haplotypes of all 13 maternal gDNA by linking the haplotype 1 2 blocks assembled by the barcoded reads. 1 3
The plasma DNA samples from 13 carrier mothers were target sequenced in the DMD 1 4 region. The fraction of cffDNA ranged from 7.45% to 15.39% (Table 3 ). We used 1 5
informative SNPs (average 701, Table 3 ) to construct the fetal haplotypes and 1 6 performed HMM to infer the genotype of fetal DMD. The results of NIPD showed 1 7 that four fetuses had inherited the Hap0 maternal haplotype, including two female 1 8 carriers (F01and F08) and two affected male fetuses (F02 and F07), and that seven 1 9 fetuses had inherited the Hap1 maternal haplotype, including six normal female 2 0 fetuses (F03, F04, F06, F09, F10, F11and F12) and two normal male fetuses (F05 and 2 1 F13) (Table 3 and Figure 1 ).
2
To further evaluate the performance of the direct haplotype-based NIPD, we 2 3 performed targeted capture sequencing in CV samples, and all families had the same 2 4 results as NIPD (Table 3) . Traditional prenatal diagnostic methods, including chorionic villus sampling, 2 amniocentesis, and umbilical cord puncture can be invasive and may put both the 3 fetus and the pregnant woman at risk. The NIPD method is simpler and safer than 4 invasive diagnosis because it only requires blood testing. Since the introduction of 5 NIPD to clinical practice in 2011 12 , it has been widely implemented and is currently 6 offered in over 60 countries 13 . NIPD was initially used to test for Down's Syndrome 7 and other forms of fetal aneuploidy by using maternal plasma cell-free fetal DNA 14 . 8
Now, it is also used for testing for monogenic diseases 6 . However, the limitations of 9 NIPD applications in determining monogenic disorder are becoming more prominent 1 0 as it requires genomic data from parents and the proband to resolve the parental 1 1
haplotypes. 1 2
To the best of our knowledge, two methods have recently been proposed to overcome locus amplification (TLA)-based haplotype phasing of the two parents with targeted 1 7 sequencing of cell-free DNA for noninvasive prenatal testing of families without a 1 8 first affected child 15 . These two-direct haplotype-based NIPD methods could 1 9 accurately deduce the fetal mutation status without relying on the availability of DNA 2 0 from the proband. In comparison, targeted haplotyping is less expensive, and 2 1 linked-read sequencing has an advantage in recombination events analysis. The 2 2 application of the two approaches in the case of DMD requires further exploration. 2 3
In this study, we first directly resolved the maternal haplotypes by performing 2 4 linked-read sequencing, and then successfully predicted the genotype of fetal DMD 2 5 by using the NIPD method in all 13 families. Gender identification is essential for the 2 6
NIPD of X-linked recessive genetic diseases. We determine the sex of the fetus based 2 7 on the average depth and the coverage of the target region in chromosome Y in the 2 8 plasma samples, as described in our previous work 16 . 1 Due to the limited researches in this area to date, more studies are needed to prove its 2 clinical feasibility. Our study demonstrated that the direct haplotype-based method 3 could provide accurate fetal genotype information on DMD without the proband, 4 meaning that it could be an additional option for the NIPD of DMD. 5
Conclusion 6
The direct haplotype-based approach for DMD has potential for introduction for 7 clinical service. To the best of our knowledge, this is the largest cohort without the 8 probands for NIPD of DMD. Further studies should aim to refine the methodology, 9 reduce the cost, and adopt this approach for a larger population with a wide range of 1 0 genetic disorders. We thank all participants in this study for their collaborations. 
